Skip to main content

Table 2 Demographic and Baseline characteristics of the subjects eligible for the trial

From: Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects

Characteristics Placebo Meratrim
(n = 30) (n = 30)
Sex ((n) male + (n) female) 14 M + 16 F 10 M + 20 F
Age (years) 39.47 ± 1.73 36.63 ± 1.64
Height (meters) 1.65 ± 0.017 1.63 ± 0.02
Body weight (kg) 76.56 ± 1.64 75.93 ± 1.91
Body mass index (kg/m2) 28.20 ± 0.24 28.48 ± 0.25
Waist circumference (cm) 103.30 ± 1.53 102.00 ± 1.59
Hip circumference (cm) 108.70 ± 1.88 108.60 ± 1.59
Waist/Hip ratio 0.96 ± 0.017 0.94 ± 0.013
Triglycerides (mg/dL) 200.50 ± 8.16 194.20 ± 8.96
Total cholesterol (mg/dL) 184.90 ± 6.18 168.80 ± 5.37
LDL (mg/dL) 108.20 ± 5.97 94.67 ± 4.73
HDL (mg/dL) 36.60 ± 0.42 35.27 ± 0.51
LHR 2.94 ± 0.15 2.68 ± 0.12
VLDL (mg/dL) 40.13 ± 1.67 38.83 ± 1.78
Fasting blood glucose (mg/dL) 99.47 ± 1.82 95.60 ± 1.99
  1. Values represent mean ± SE
  2. LDL low-density lipoproteins; HDL high-density lipoprotein; LHR LDL/HDL ratio; VLDL very low-density lipoproteins